Debiopharm Innovation Fund

MedaSystems is a developer of a cloud-based platform that facilitates the management of requests for experimental therapies. The platform is designed to streamline various processes through configurable workflows and a form builder that captures complex, structured, therapy-specific data. It incorporates task management and tracking features, and integrates with machine learning libraries, enabling collaboration between manufacturers and physicians. MedaSystems supports a range of initiatives, including expanded access programs, named patient programs, investigator-sponsored trial requests, and post-trial access, thereby enhancing global access to investigational medicines.

StratifAI is a precision oncology company that develops multimodal AI models to extract prognostic insights from routine histology images and clinical data. Their expertise lies in biomarker discovery, clinical trial data analysis, large language models, and multimodal data integration, aiming to guide treatment decisions and facilitate the development of personalized cancer therapies by pharmaceutical companies.

Risklick is a technology company that develops a pioneering data-driven tool to identify similar clinical trials and assess risks in the early stages of protocol design. It aims to address the high failure rate of clinical trials (up to 90% in the early stage) by making risk assessment more efficient and accurate. The company's platform employs machine learning and artificial intelligence to analyze and mitigate risks at any stage of clinical trial development, helping data scientists, risk analysts, and experts collaborate with trial designers to optimize protocols before trials commence.

MedaSystems is a developer of a cloud-based platform that facilitates the management of requests for experimental therapies. The platform is designed to streamline various processes through configurable workflows and a form builder that captures complex, structured, therapy-specific data. It incorporates task management and tracking features, and integrates with machine learning libraries, enabling collaboration between manufacturers and physicians. MedaSystems supports a range of initiatives, including expanded access programs, named patient programs, investigator-sponsored trial requests, and post-trial access, thereby enhancing global access to investigational medicines.

OmicsChart is a technology company specializing in a data and biomarker discovery platform for cancer research. It aims to streamline precision oncology data sharing, fostering collaboration and accelerating clinical research. The platform unifies disparate cancer data, enabling secure, instantaneous patient data sharing and facilitating the scalable application of machine learning methods on real-world data. This ultimately expedites the journey from discovery to effective treatments, potentially saving years in the research process.

Altis Labs is a computational imaging company that leverages artificial intelligence to enhance clinical trials. By developing an advanced software platform, Altis enables biopharmaceutical companies to process their clinical trial data in real-time, predicting drug efficacy with improved accuracy. The company's unique approach is underpinned by the creation of a comprehensive multimodal training database that integrates longitudinal imaging with demographic, clinical, and molecular data, as well as extensive outcomes data. This innovative use of AI allows biopharma firms to measure treatment effects more effectively from existing data, thereby increasing the speed and success rate of late-stage trials and reducing the overall time and cost associated with bringing new drugs to market.

Concr is a techbio company focused on enhancing cancer treatment by predicting patient responses to various therapies. Utilizing methods from astrophysics, Concr's innovative approach allows for iterative learning from diverse data sources throughout a drug's clinical journey, resulting in accurate multi-modal tumor models without relying on extensive data sets. Its cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses and biomarkers, and conduct standard bioinformatics analyses. This technology aims to identify optimal treatments for individual patients, reduce treatment resistance, and facilitate personalized cancer management. Headquartered in London with a subsidiary in Brisbane, Australia, Concr is backed by several investors, including the University of Cambridge Enterprise and Oncology Ventures.

Genialis, Inc. is a computational precision medicine company that specializes in developing a web-based software platform for biological data management and analysis. Founded in 2015 and based in Houston, Texas, the platform provides a suite of visual analytics and bioinformatics tools, facilitating the storage, analysis, and sharing of biological data while ensuring transparency and security. The system automates primary analyses to enhance reproducibility and allows non-computational experts to access advanced downstream analyses. Genialis focuses on unraveling complex biology to identify actionable biomarkers, which aids pharmaceutical companies in developing effective drugs and diagnostics that improve treatment decisions. The company's efforts aim to enhance translational research and clinical development, ultimately benefiting patients and their families.

Iktos is a French company focused on artificial intelligence and robotic solutions for medicinal chemistry and drug design. It offers a proprietary generative AI technology that optimizes molecule design for small molecule discovery projects, significantly enhancing productivity in pharmaceutical research and development. Iktos provides its innovative solutions through its SaaS platforms, Makya™ for generative drug design and Spaya™ for retrosynthesis, while also engaging in strategic partnerships with pharmaceutical companies to accelerate drug discovery. Additionally, Iktos has developed an AI-driven synthesis automation platform, Iktos Robotics, which expedites the Design-Make-Test-Analyze cycle in drug development. The company is also advancing its own pipeline of drug candidates aimed at oncology and autoimmune diseases. In March 2023, Iktos secured a significant financing round, and in July 2024, it enhanced its capabilities by acquiring Synsight, which adds a biology platform for discovering drugs targeting Protein-Protein and RNA-Protein interactions.

YonaLink operates a global network of over 30,000 medical centers, focusing on the collection and management of clinical trial data. The company offers a platform that streamlines the migration of clinical research data from electronic health records to electronic data capture systems, ensuring a secure and automated process. By enhancing trial efficiency and data quality, YonaLink alleviates the burden on medical center staff and broadens access to innovative patient care opportunities. Its solutions also aim to accelerate drug and medical device development while promoting patient diversity and enrollment in clinical trials, ultimately enabling healthcare providers and researchers to achieve faster and more accurate data capture.

Mika is a digital platform that empowers cancer patients. It aims to help improve cancer patients' mental health and well-being. Mika was created in collaboration with leading research institutions. The company was established in 2017 and is headquartered in Berlin, Germany.

VivoSense, also known as Vivonoetics, is a data analysis and software company focused on providing wearable sensor physiological monitoring solutions for research and clinical trials. The company develops digital clinical measures designed to enhance patient research and care by delivering digital biomarkers derived from wearable sensor data. This platform allows researchers to collect and analyze real-world data accurately, facilitating informed decision-making and risk evaluation associated with various medical treatments in regulated clinical environments. Through its innovative approach, VivoSense aims to improve the efficiency and effectiveness of clinical research.

Nucleai Ltd. is a spatial biology company that has developed an AI-powered pathology platform focused on enhancing drug development and improving patient outcomes. Founded in 2017 and headquartered in Tel Aviv-Yafo, Israel, Nucleai's technology utilizes unique tissue datasets and machine learning algorithms to analyze biopsy samples and detect various cancers, including prostate, breast, and gastrointestinal diseases. The platform aims to improve the interpretation of pathology results, thereby increasing the efficacy of clinical trials and fostering better patient care. Nucleai collaborates with leading pharmaceutical companies, licensing its platform for internal use and participating in biomarker discovery projects. By transforming healthcare through artificial intelligence, Nucleai strives to enable researchers to identify novel biomarkers that predict therapeutic responses and enhance understanding of complex biological phenomena.

VeriSIM Life, Inc. is a biotechnology company based in San Francisco, California, established in 2017. It specializes in developing disease-specific biosimulation models that utilize artificial intelligence to predict the clinical outcomes of new drugs prior to clinical trials. The company offers a range of tailored solutions designed for pre-clinical and clinical programs, all centered around its validated BIOiSIM platform, which accommodates small molecules, large molecules, and viruses. By replacing traditional animal testing with sophisticated software simulations, VeriSIM Life aims to enhance the accuracy and efficiency of drug development, ultimately contributing to increased human life expectancy and the personalization of healthcare treatments.

Mekonos Inc. specializes in the design, development, and production of gene and cell therapies, focusing on a proprietary cell-engineering platform that utilizes advanced silicon technology. Founded in 2017 and based in San Francisco, the company has created an integrated system-on-a-chip, which incorporates micro-electromechanical systems (MEMS) to enable the precise injection of single cells using nanoneedles in a parallel architecture. This innovative approach aims to industrialize genome editing and enhance drug discovery and development processes. Mekonos' technology allows for scalable and reliable manufacturing of engineered therapies aimed at addressing genetic diseases, including various forms of cancer, and supports healthcare providers in delivering diverse therapeutic molecules across multiple cell types.

Carevive Systems, Inc. is a company that develops a platform designed to enhance cancer care delivery and patient engagement. The platform includes Carevive PROmpt, which serves as a cancer clinical practice and patient engagement software for treatment planning, symptom management, and survivorship care, as well as offering analytics and evidence-based care plans. It also features a Treatment Care Plans engine, which utilizes rules technology for personalized treatment strategies, and a Navigation/Care Coordination module that facilitates patient eligibility tracking and care plan adherence. Additionally, Carevive Systems provides tools for risk stratification, symptom triage, and patient symptom trending, allowing clinicians to monitor patient progress effectively. The company, based in North Miami, Florida, was incorporated in 2013 and rebranded from On Q Health, Inc. in 2015. Through its solutions, Carevive Systems aims to improve clinical outcomes and support oncology practices in adapting to value-based care models.

Voluntis, established in 2001, specializes in developing digital therapeutic solutions for diabetes, oncology, and other therapeutic areas. The company offers products such as Insulia, Diabeo, Oleena, and AstraZeneca, which provide automated insulin dose recommendations, patient-specific dosage suggestions, and management of side effects like hypertension and diarrhea. Voluntis collaborates with pharmaceutical companies like Bristol-Myers Squibb to co-develop digital therapeutics for oncology. Headquartered in France with operations in the U.S., Voluntis aims to enhance patient outcomes and healthcare system efficiency through innovative, secure, and patient-centric digital health solutions.

Oncomfort SA specializes in developing innovative digital sedation solutions aimed at alleviating pain and anxiety in patients undergoing medical procedures. Founded in 2017 and based in Wavre, Belgium, the company offers Sedakit, a portable, all-in-one device that delivers digital sedation therapy. This therapy integrates clinical hypnotherapy and various therapeutic techniques through virtual reality, providing a non-pharmacological approach to managing anxiety and discomfort. By utilizing evidence-based methods, Oncomfort's technology enhances patient comfort throughout their medical journey, addressing the psychological and emotional challenges associated with medical treatments.

Nucleai Ltd. is a spatial biology company that has developed an AI-powered pathology platform focused on enhancing drug development and improving patient outcomes. Founded in 2017 and headquartered in Tel Aviv-Yafo, Israel, Nucleai's technology utilizes unique tissue datasets and machine learning algorithms to analyze biopsy samples and detect various cancers, including prostate, breast, and gastrointestinal diseases. The platform aims to improve the interpretation of pathology results, thereby increasing the efficacy of clinical trials and fostering better patient care. Nucleai collaborates with leading pharmaceutical companies, licensing its platform for internal use and participating in biomarker discovery projects. By transforming healthcare through artificial intelligence, Nucleai strives to enable researchers to identify novel biomarkers that predict therapeutic responses and enhance understanding of complex biological phenomena.

Carevive Systems, Inc. is a company that develops a platform designed to enhance cancer care delivery and patient engagement. The platform includes Carevive PROmpt, which serves as a cancer clinical practice and patient engagement software for treatment planning, symptom management, and survivorship care, as well as offering analytics and evidence-based care plans. It also features a Treatment Care Plans engine, which utilizes rules technology for personalized treatment strategies, and a Navigation/Care Coordination module that facilitates patient eligibility tracking and care plan adherence. Additionally, Carevive Systems provides tools for risk stratification, symptom triage, and patient symptom trending, allowing clinicians to monitor patient progress effectively. The company, based in North Miami, Florida, was incorporated in 2013 and rebranded from On Q Health, Inc. in 2015. Through its solutions, Carevive Systems aims to improve clinical outcomes and support oncology practices in adapting to value-based care models.

BC Platforms is a technology company that specializes in providing a unique data and technology platform for life sciences and healthcare companies. Their Data Access Platform offers access to valuable real-world data (RWD), clinical, genomics, and omics data through a data-as-a-service model. This enables pharmaceutical companies to enhance various use cases within the research and development continuum, from early discovery to post-market processes. The company's technology platform also supports healthcare providers and life science companies in producing, managing, and analyzing complex genomic data as a clinical decision-support solution. BC Platforms' Data Partner Network covers over 22 million life-years of highly curated patient data from around the world, ensuring compatibility with relevant technical standards and compliance with local privacy laws.

Kaiku Health Oy is a digital health company based in Helsinki, Finland, focused on enhancing the quality of life for patients, particularly those undergoing cancer treatment. Founded in 2012, the company offers a user-centered platform that facilitates communication between patients and medical staff in multiple languages, including Swedish, English, German, and Finnish. Its software is designed to monitor patient-reported outcomes and track symptoms intelligently, allowing clinics to optimize care through timely interventions and improved efficiency. Kaiku Health serves over 30 hospitals and clinics across Finland, Sweden, and Switzerland, helping to streamline workflows and prioritize clinical actions. The company evolved from its original name, Netmedi Oy, in 2017 and operates as a subsidiary of Elekta AB. A dedicated team of over 20 employees drives its mission, supported by various venture capital funds and the Finnish Funding Agency for Innovation.

ABAC Therapeutics S.A., based in Barcelona, Spain, specializes in the development of precision antimicrobial agents aimed at treating multidrug-resistant (MDR) Gram-negative infections. Established in 2014, the company utilizes its innovative PasNas drug discovery platform to identify pathogen-specific antibacterial properties of various molecules. This platform not only focuses on potent antibacterial activity but also emphasizes the importance of favorable pharmacokinetics and toxicological profiles to enhance the likelihood of success in clinical development. ABAC Therapeutics seeks to provide first-in-class therapeutic alternatives for patients suffering from infections caused by antibiotic-resistant bacterial pathogens, particularly targeting the significant challenge posed by the major MDR Gram-negative bacteria. As of November 2019, the company operates as a subsidiary of Tibidabo Ventures.

BC Platforms is a technology company that specializes in providing a unique data and technology platform for life sciences and healthcare companies. Their Data Access Platform offers access to valuable real-world data (RWD), clinical, genomics, and omics data through a data-as-a-service model. This enables pharmaceutical companies to enhance various use cases within the research and development continuum, from early discovery to post-market processes. The company's technology platform also supports healthcare providers and life science companies in producing, managing, and analyzing complex genomic data as a clinical decision-support solution. BC Platforms' Data Partner Network covers over 22 million life-years of highly curated patient data from around the world, ensuring compatibility with relevant technical standards and compliance with local privacy laws.

Coorpacademy S.A. is a Swiss company based in Lausanne, established in 2013. It specializes in developing online training courses and innovative learning solutions, including MOOCs. The company offers a learning experience platform that features a diverse catalog of training courses, which are designed to provide short, accessible sessions that users can engage with at any time and on various devices. This platform aims to revolutionize digital learning for employees by delivering customized content tailored to individual needs. Coorpacademy was founded by Frederick Benichou, Jean-Marc Tassetto, and Arnauld Mitre.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

KeyLemon S.A., founded in 2008 by Gilles Florey and Yann Rodriguez in Martigny, Switzerland, specializes in biometric authentication technology, particularly through face recognition. The company aims to provide a seamless and secure user experience by allowing devices to recognize their owners naturally, eliminating the need for passwords. KeyLemon has developed innovative solutions, including its flagship product, Oasis, which enables mobile authentication by simply taking a selfie. This technology is designed for various applications, enhancing secure access to high-value services such as banking and payment across multiple devices and systems. Over the years, KeyLemon has established itself as a leader in biometric solutions, serving a diverse clientele globally while remaining committed to continuous improvement in user recognition and security. As of 2018, KeyLemon operates as a subsidiary of ams AG.

Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as well as its high sensitivity and specificity.

Searchbox is a software company specializing in search technologies, with strong areas of expertise in cognitive sciences, data mining and computer sciences. Through its innovative technologies, Searchbox fundamentally changes the way people interact and consume information. Through highly customizable cloud based search solutions and plugins for Solr, these technologies are readily available for usage with a minimal amount of tinkering.

Neovacs is a biotechnology company founded in 1993 as a spin-off from the Pierre & Marie Curie University in Paris by Professor Daniel Zagury, a prominent immunologist. The company specializes in the development of therapeutic vaccines known as "Kinoids," which are designed to treat a range of conditions including autoimmune diseases, allergies, and cancer. Neovacs holds an extensive patent portfolio and is recognized for its innovative approach to vaccine development, particularly in creating vaccines that target human cytokines and immunosuppressive viral proteins. Unlike traditional monoclonal antibody treatments that provide exogenous therapies, Neovacs' therapeutic vaccines promote a robust natural polyclonal antibody response in patients, positioning the company as a pioneer in the field of immunotherapy.